Long-time Alzheimer's disease researchers at Washington University School of Medicine in St. Louis (WashU) are partnering with three biopharmas – Abbvie Inc., Biogen Inc. and Eli Lilly and Co. – in a two-year program to investigate the buildup and clearance of tau protein in the brains of patients with the disease.